Search PubMed⌕ Search

Biomedical subjects

W R Wilson

Publications and source records attributed to W R Wilson.

At least 379 records · Page 21Linked to original sources

Effects of triiodothyronine-induced hypermetabolism on factor 8 and fibrinogen in man.

Triiodothyronine (liothyronine sodium) (400-500 mug/day for 14 days) was given to six normal subjects. Factor VIII (antihemophilic globulin) activity increased from 109 to 167% (P < 0.05); fibrinogen increased from 344 to 581 mg/100 ml (P < 0.01). To test whether the increases in factor VIII activity and fibrinogen were mediated by beta adrenergic receptors, propranolol (20 mg every 6 hr) was given orally to four other normal subjects in addition to triiodothyronine for 14 days. Factor VIII increased from 100 to 161%; fibrinogen increased from 374 to 564% (P < 0.01). Factor VIII activity did not change in a severe classical hemophiliac made hypermetabolic with triiodothyronine, but it increased from 39 to 82% in a patient with von Willebrand's disease. Triiodothyronine-induced hypermetabolism increased the incorporation of selenomethionine-(75)Se into plasma fibrinogen. These results suggest that the increases in clotting factor activity during triiodothyronine-induced hypermetabolism reflect an effect of increased protein synthesis rather than enhanced stimulation of beta adrenergic receptors.

Basal Metabolism↗

A method for combined dacryocystorhinostomy with external ethmoidectomy.

Severe polypoid rhinosinusitis requiring external ethmoid surgery may be seen in conjunction with partial or complete nasolacrimal obstruction. When this obstruction is associated with persistent, unresolved lacrimal symptoms, it is sometimes appropriate to combine surgical procedures, thereby avoiding separate lacrimal surgery. A method combining dacryocystorhinostomy (DCR) with external ethmoidectomy is described. The anatomy involved in this procedure and the indications for it are discussed.

Dacryocystorhinostomy↗

Selection of cephalosporins for hospital formularies.

Because of the large number of cephalosporins available for use, and for economic reasons, most hospitals have restricted the number of cephalosporins for inclusion on hospital formularies. No more than one first-generation oral and parenteral cephalosporin is necessary. The second- and third-generation oral cephalosporins are more active in vitro against Haemophilus influenzae and Enterobacteriaceae, and the selection of one of these drugs should be based primarily on acquisition cost. There is usually minimal, if any, need for a second-generation parenteral cephalosporin on hospital formularies. The choice of a single third-generation parenteral cephalosporin should be made primarily on the cost of equivalent daily dosages. A single antipseudomonal cephalosporin should be included in the hospital formulary, and the selection should be based on cost and availability.

Administration, Oral↗